ME/CFS Skeptic
Senior Member (Voting Rights)
Research suggestions and ideas
Actimetry and wearables
The key clinical problem in ME/CFS is exertion intolerance. I think we need to be able to measure that objectively. I think there is an analogy with the inability to move rapidly and smoothly in Parkinsonism. The neurologists have made progress in documenting this with actimetry - including describing on-off phenomena. Actimetry in ME/CFS has mostly looked at just quantity of activity but I think it needs to be used to look at PATTERNS of impaired activity so that these can be tracked objectively over long periods. The technical term for this is apparently 'motor fatigue'. That is to say not a sense of fatigue but a behavioural pattern that can be studied objectively. Only when we understand these patterns will we know what we are trying to explain. I think it very likely that if we really knew what the activity deficit was we would know we are not looking for a metabolic defect, for instance. [The most compelling ME/CFS research needs]
Wearables are cheap and the data can be uploaded easily. Patients worlwide are a rich resource and companies making bioharnesses to measure physiology and activity are interested in research and some prepared to donate the equipment. We can put people on the moon and train elite athletes yet can't devise an effective physiologically guided activity program for a person with ME/CFS and its associated exercise intolerance . It is a huge whole in the research that would be extremely profitable to address. [Potential research resources, tools, and/or materials that could help advance ME/CFS research or enable early career investigators and senior investigators new to the ME/CFS field to more easily conduct research]
Modify a Fitbit-like home measurement device that sufferers can use to report data remotely from home in an automated way. [Approaches to reduce barriers that prevent individuals with ME/CFS from participating in research. For example, these might be logistical challenges, such as difficulty traveling to a study site, or might be because of an unwillingness to undergo certain types of research protocols]
Autopsy study
A key resource would be the collection of a series of 20 sequential autopsy brains on moderate to severe patients commiting suicide. A central consistent processing facility with controls should be used and blinded tissue samples sent to three independent neuropathologists. An important aim would be to exclude any so far missed patterns of pathology but positive findings would be of geat help. Such a proposal should be set up prospectively with government funding making use of something like the UK Queen Square RNHND brain bank facility . I think Nacul and colleagues have raised this in 2014. [The most compelling ME/CFS research needs]
A US Data Repository and Biobank
Data Repository and Biobank: Finalize a clearly articulated plan to establish and maintain NIH-funded centralized data and biospecimen repositories, which can store anonymized clinical and research data, including imaging data and biospecimens collected from well-characterized patients in past, current, and future research studies. These repositories should be fully operational within two years and accessible by outside researchers. The repositories can be extensions of existing repositories that are storing ME data and biospecimens or built from scratch. The current efforts focused on just the data generated by the NIH supported CRCs must be expanded to include institutions not funded in the CRC grant, provided they share their inclusion criteria and specifics regarding the manner in which the specimens were gathered and stored. [The most compelling ME/CFS research needs]
One of the most daunting aspects for someone who wishes to enter the field is access to quality samples that are accompanied with detailed clinical data. The UK biobank is helpful but will not be able to supply all projects. I believe that a US ME/CFS biobank is needed, developed by a specific project designed to collect no-strings-attached samples from subjects selected by ME/CFS expert physicians. The number of such physicians is rapidly dwindling as many who entered the fields during the ME/CFS outbreaks of the 1980s have retired or are at retirement age now. I suggest that an RFA needs to be issued for collection of samples that would go into an NIHsponsored repository, from which researchers could request samples by a non-cumbersome application process. [Potential research resources, tools, and/or materials that could help advance ME/CFS research or enable early career investigators and senior investigators new to the ME/CFS field to more easily conduct research]
Many patients would love to participate in research but live too far from a research center and/or are (much) too ill to travel. Establishing a large biobank, maybe following the template of the UK MEbiobank, could help overcome some of these access problems. [Approaches to reduce barriers that prevent individuals with ME/CFS from participating in research. For example, these might be logistical challenges, such as difficulty traveling to a study site, or might be because of an unwillingness to undergo certain types of research protocols]
Test off-label treatments
NIH should also leverage all funding opportunities including both clinical efficacy trials for interventions already being used offlabel and for exploratory trials to identify responder/non-responder subgroups and investigate underlying biological variables driving disparate outcomes. To best leverage this opportunity, we recommend NIH issue a targeted funding announcement with set-aside funds to support the establishment of a Clinical Trials and Interventions Consortium to develop the network of clinical sites who participate in trials and to further develop the instrumentation, methods, and trial design to ensure success of these trials. We also recommend NIH institutes prioritize and provide funding for intervention trials already being used off-label in clinical practice. [The most compelling ME/CFS research needs]
Change in vision as objective marker
One possible objective marker could be a change in vision. I often claim to have worse vision when worse - this is something like worsening myopia. Although the change is not a huge scale, it may be true for other people with ME/CFS. REM have been shown to be abnormal in MS patients performing a fatiguing task (Ferreira M., 2017). [Relevant considerations and strategies for clinical ME/CFS research, including the development and validation of data standards and outcome measures]
Adequate vocabulary
One crucial problem is a lack of adequate vocabulary. Most of the common labels used in this disease are unrepresentative and unnecessarily vague. It is unfortunate that “I feel sick” is an inadequate description, but nothing of value was gained by arbitrarily preferring instead the even more inadequate obsession with fatigue, a secondary symptom of ME, a term that is used to provide various meanings from sleepiness to the common “subjective sensation of tiredness”, a completely inadequate and misleading definition of ME. […]It’s likely that a reliable test will require less reliance on language and more on objective measures, but there are clear advantages to creating a common and accurate idiom that actually relates to the lived experience of the disease while carrying proper meaning to researchers and clinicians, as initial clinical consultations will require the proper use of accurate terms to guide the diagnostic process towards a proper (future) test. [Relevant considerations and strategies for clinical ME/CFS research, including the development and validation of data standards and outcome measures]
Actimetry and wearables
The key clinical problem in ME/CFS is exertion intolerance. I think we need to be able to measure that objectively. I think there is an analogy with the inability to move rapidly and smoothly in Parkinsonism. The neurologists have made progress in documenting this with actimetry - including describing on-off phenomena. Actimetry in ME/CFS has mostly looked at just quantity of activity but I think it needs to be used to look at PATTERNS of impaired activity so that these can be tracked objectively over long periods. The technical term for this is apparently 'motor fatigue'. That is to say not a sense of fatigue but a behavioural pattern that can be studied objectively. Only when we understand these patterns will we know what we are trying to explain. I think it very likely that if we really knew what the activity deficit was we would know we are not looking for a metabolic defect, for instance. [The most compelling ME/CFS research needs]
Wearables are cheap and the data can be uploaded easily. Patients worlwide are a rich resource and companies making bioharnesses to measure physiology and activity are interested in research and some prepared to donate the equipment. We can put people on the moon and train elite athletes yet can't devise an effective physiologically guided activity program for a person with ME/CFS and its associated exercise intolerance . It is a huge whole in the research that would be extremely profitable to address. [Potential research resources, tools, and/or materials that could help advance ME/CFS research or enable early career investigators and senior investigators new to the ME/CFS field to more easily conduct research]
Modify a Fitbit-like home measurement device that sufferers can use to report data remotely from home in an automated way. [Approaches to reduce barriers that prevent individuals with ME/CFS from participating in research. For example, these might be logistical challenges, such as difficulty traveling to a study site, or might be because of an unwillingness to undergo certain types of research protocols]
Autopsy study
A key resource would be the collection of a series of 20 sequential autopsy brains on moderate to severe patients commiting suicide. A central consistent processing facility with controls should be used and blinded tissue samples sent to three independent neuropathologists. An important aim would be to exclude any so far missed patterns of pathology but positive findings would be of geat help. Such a proposal should be set up prospectively with government funding making use of something like the UK Queen Square RNHND brain bank facility . I think Nacul and colleagues have raised this in 2014. [The most compelling ME/CFS research needs]
A US Data Repository and Biobank
Data Repository and Biobank: Finalize a clearly articulated plan to establish and maintain NIH-funded centralized data and biospecimen repositories, which can store anonymized clinical and research data, including imaging data and biospecimens collected from well-characterized patients in past, current, and future research studies. These repositories should be fully operational within two years and accessible by outside researchers. The repositories can be extensions of existing repositories that are storing ME data and biospecimens or built from scratch. The current efforts focused on just the data generated by the NIH supported CRCs must be expanded to include institutions not funded in the CRC grant, provided they share their inclusion criteria and specifics regarding the manner in which the specimens were gathered and stored. [The most compelling ME/CFS research needs]
One of the most daunting aspects for someone who wishes to enter the field is access to quality samples that are accompanied with detailed clinical data. The UK biobank is helpful but will not be able to supply all projects. I believe that a US ME/CFS biobank is needed, developed by a specific project designed to collect no-strings-attached samples from subjects selected by ME/CFS expert physicians. The number of such physicians is rapidly dwindling as many who entered the fields during the ME/CFS outbreaks of the 1980s have retired or are at retirement age now. I suggest that an RFA needs to be issued for collection of samples that would go into an NIHsponsored repository, from which researchers could request samples by a non-cumbersome application process. [Potential research resources, tools, and/or materials that could help advance ME/CFS research or enable early career investigators and senior investigators new to the ME/CFS field to more easily conduct research]
Many patients would love to participate in research but live too far from a research center and/or are (much) too ill to travel. Establishing a large biobank, maybe following the template of the UK MEbiobank, could help overcome some of these access problems. [Approaches to reduce barriers that prevent individuals with ME/CFS from participating in research. For example, these might be logistical challenges, such as difficulty traveling to a study site, or might be because of an unwillingness to undergo certain types of research protocols]
Test off-label treatments
NIH should also leverage all funding opportunities including both clinical efficacy trials for interventions already being used offlabel and for exploratory trials to identify responder/non-responder subgroups and investigate underlying biological variables driving disparate outcomes. To best leverage this opportunity, we recommend NIH issue a targeted funding announcement with set-aside funds to support the establishment of a Clinical Trials and Interventions Consortium to develop the network of clinical sites who participate in trials and to further develop the instrumentation, methods, and trial design to ensure success of these trials. We also recommend NIH institutes prioritize and provide funding for intervention trials already being used off-label in clinical practice. [The most compelling ME/CFS research needs]
Change in vision as objective marker
One possible objective marker could be a change in vision. I often claim to have worse vision when worse - this is something like worsening myopia. Although the change is not a huge scale, it may be true for other people with ME/CFS. REM have been shown to be abnormal in MS patients performing a fatiguing task (Ferreira M., 2017). [Relevant considerations and strategies for clinical ME/CFS research, including the development and validation of data standards and outcome measures]
Adequate vocabulary
One crucial problem is a lack of adequate vocabulary. Most of the common labels used in this disease are unrepresentative and unnecessarily vague. It is unfortunate that “I feel sick” is an inadequate description, but nothing of value was gained by arbitrarily preferring instead the even more inadequate obsession with fatigue, a secondary symptom of ME, a term that is used to provide various meanings from sleepiness to the common “subjective sensation of tiredness”, a completely inadequate and misleading definition of ME. […]It’s likely that a reliable test will require less reliance on language and more on objective measures, but there are clear advantages to creating a common and accurate idiom that actually relates to the lived experience of the disease while carrying proper meaning to researchers and clinicians, as initial clinical consultations will require the proper use of accurate terms to guide the diagnostic process towards a proper (future) test. [Relevant considerations and strategies for clinical ME/CFS research, including the development and validation of data standards and outcome measures]